[PDF] nature.com

The PARTNER trial of neoadjuvant olaparib in triple-negative breast cancer

JE Abraham, K Pinilla, A Dayimu, L Grybowicz… - Nature, 2024 - nature.com
PARTNER is a prospective, phase II-III, randomised controlled clinical trial, which recruited
patients with Triple Negative Breast Cancer (TNBC) 1, 2, who were gBRCA wild type …
被引用次数：1 相关文章 所有 10 个版本

Abstract P3-10-05: Preliminary safety data from stage 1 and 2 of the phase II/III PARTNER trial: Addition of olaparib to platinum-based neoadjuvant chemotherapy in …

KP Alba, E McMurtry, AL Vallier, L Grybowicz… - Cancer Research, 2020 - AACR
Background: Triple negative breast cancers (TNBCs) are an aggressive and diverse
subgroup with no specific targeted therapies currently available. Basal TNBCs show some …
被引用次数：10 相关文章 所有 2 个版本

PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative …

HM Earl, AL Vallier, W Qian, L Grybowicz, S Thomas… - 2017 - ascopubs.org
TPS591 Background: No specific targeted therapies are available for Triple Negative Breast
Cancers (TNBC), an aggressive and diverse subgroup. The basal TNBC sub-group show …
被引用次数：12 相关文章

PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative …

J Abraham, AL Vallier, W Qian, A Machin, L Grybowicz… - 2018 - ascopubs.org
TPS605 Background: No specific targeted therapies are available for triple negative breast
cancer (TNBC), an aggressive and diverse subgroup. The basal TNBC subgroup show …
被引用次数：9 相关文章 所有 3 个版本

OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA 1/2 mutation …

ANJ Tutt, B Kaufman, RD Gelber, E Mc Fadden… - 2015 - ascopubs.org
TPS1109 Background: In a Phase II proof-of-concept study (NCT00494234), treatment with
the PARP inhibitor olaparib (Lynparza; 400 mg twice daily [bid]; capsules) resulted in …
被引用次数：26 相关文章

PARTNER: A randomized, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in patients with …

L Drewett, R Lucey, KA Pinilla, L Grybowicz, J Wulff… - 2022 - ascopubs.org
TPS619 Background: Triple negative breast cancers (TNBCs) are a biologically diverse and
aggressive subgroup lacking targeted therapy. TNBC and germline BRCA (gBRCA) breast …
被引用次数：5 相关文章 所有 3 个版本
[PDF] jamanetwork.com

Concurrent olaparib and radiotherapy in patients with triple-negative breast cancer: the phase 1 olaparib and radiation therapy for triple-negative breast cancer trial

P Loap, D Loirat, F Berger, M Rodrigues… - Jama …, 2022 - jamanetwork.com
Importance Triple-negative breast cancer (TNBC) cells are sensitive to poly (adenosine
diphosphate ribose) polymerase (PARP) inhibitors used as radiosensitizers. Whether …
被引用次数：28 相关文章 所有 5 个版本
[PDF] frontiersin.org

Clinical, radiometabolic and immunologic effects of olaparib in locally advanced triple negative breast cancer: the OLTRE window of opportunity trial

F Schettini, SP Corona, F Giudici, C Strina… - Frontiers in …, 2021 - frontiersin.org
Introduction Olaparib is effective in metastatic triple negative breast cancer (TNBC) carrying
germline mutations in DNA damage repair (DDR) genes BRCA1/2 (g BRCA-mut). The …
被引用次数：15 相关文章 所有 15 个版本

OlympiA: a randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation …

A Tutt, B Kaufman, J Garber, R Gelber… - Annals of …, 2017 - annalsofoncology.org
Background: In a Phase II study (NCT00494234), treatment with olaparib, a potent, orally
available PARP inhibitor, exerted antitumor activity in patients (pts) with advanced BC …
被引用次数：22 相关文章 所有 3 个版本
[HTML] sciencedirect.com

[HTML][HTML] Olaparib monotherapy as primary treatment in unselected triple negative breast cancer

HP Eikesdal, S Yndestad, A Elzawahry… - Annals of oncology, 2021 - Elsevier
Background The antitumor efficacy of PARP inhibitors (PARPi) for breast cancer patients
harboring germline BRCA1/2 (gBRCA1/2) mutations is well established. While PARPi …
被引用次数：134 相关文章 所有 10 个版本